CytomX Unveils $250 Mln Offering Of Shares And Warrants To Advance Varseta-M And Other Pipeline

CytomX Therapeutics has commenced an underwritten public offering of $250.0 million of shares and pre-funded warrants. The raise is a straightforward capital market transaction that may dilute existing equity and could move the stock by a few percentage points pending deal terms and use of proceeds.

Analysis

CytomX Therapeutics has commenced an underwritten public offering of $250.0 million of shares and pre-funded warrants. The raise is a straightforward capital market transaction that may dilute existing equity and could move the stock by a few percentage points pending deal terms and use of proceeds.